stoxline Quote Chart Rank Option Currency Glossary
  
Amylyx Pharmaceuticals, Inc. (AMLX)
2.015  0.015 (0.75%)    07-19 13:32
Open: 2
High: 2.04
Volume: 628,209
  
Pre. Close: 2
Low: 1.93
Market Cap: 137(M)
Technical analysis
2024-07-19 1:18:11 PM
Short term     
Mid term     
Targets 6-month :  2.82 1-year :  3.3
Resists First :  2.42 Second :  2.82
Pivot price 1.96
Supports First :  1.89 Second :  1.57
MAs MA(5) :  2.13 MA(20) :  1.93
MA(100) :  3.47 MA(250) :  11.74
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  53.1 D(3) :  64.9
RSI RSI(14): 52.5
52-week High :  25.47 Low :  1.57
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AMLX ] has closed below upper band by 44.3%. Bollinger Bands are 80.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 77 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.18 - 2.2 2.2 - 2.21
Low: 1.97 - 1.99 1.99 - 2
Close: 1.98 - 2 2 - 2.02
Company Description

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Headline News

Thu, 18 Jul 2024
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm - Longview News-Journal

Sun, 14 Jul 2024
Allspring Global Investments Holdings LLC Buys 15,247 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World

Wed, 10 Jul 2024
Amylyx Pharmaceuticals, Inc. (AMLX) Avexitide Acquisition Conference Call Transcript - Seeking Alpha

Tue, 09 Jul 2024
Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide - Business Wire

Tue, 09 Jul 2024
Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide - StockTitan

Thu, 09 May 2024
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 68 (M)
Shares Float 52 (M)
Held by Insiders 14.2 (%)
Held by Institutions 88.3 (%)
Shares Short 7,210 (K)
Shares Short P.Month 7,990 (K)
Stock Financials
EPS -1.08
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.76
Profit Margin -17.9 %
Operating Margin -137.8 %
Return on Assets (ttm) -12.4 %
Return on Equity (ttm) -21 %
Qtrly Rev. Growth 24.1 %
Gross Profit (p.s.) 0
Sales Per Share 5.85
EBITDA (p.s.) -1.18
Qtrly Earnings Growth 0 %
Operating Cash Flow 17 (M)
Levered Free Cash Flow 35 (M)
Stock Valuations
PE Ratio -1.89
PEG Ratio 0
Price to Book value 0.42
Price to Sales 0.34
Price to Cash Flow 8.3
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android